DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Pain Responses in Patients on Long-Term Opioid Therapy for Chronic Pain

Completed

Conditions: Chronic Pain

Interventions: Device: Quantitative Sensory Testing (QST)

First Posted Date: 2008-04-14

Last Posted Date: 2020-07-22

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 419

Registration Number: NCT00656942

Locations: 🇺🇸
MGH Center for Translational Pain Center, Boston, Massachusetts, United States

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

Early Phase 1

Completed

Conditions: Neurofibromatosis Type 1
Cutaneous Neurofibromas

Interventions: Drug: Ranibizumab

First Posted Date: 2008-04-14

Last Posted Date: 2016-07-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 11

Registration Number: NCT00657202

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Internet-Based Cervical Cytology Screening Program

Completed

Conditions: Cervical Cancer

First Posted Date: 2008-04-14

Last Posted Date: 2015-04-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 175

Registration Number: NCT00658190

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Phase 1

Conditions: Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Avastin

First Posted Date: 2008-04-03

Last Posted Date: 2020-08-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 46

Registration Number: NCT00652119

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 2 locations

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoplasmacytic Lymphoma
Angioimmunoblastic T-cell Lymphoma
Follicular Lymphoma
Low Grade B-cell Lymphoma, Not Otherwise Specified
Anaplastic Large-cell Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Small Lymphocytic Lymphoma
Peripheral T-cell Lymphoma
Diffuse Large B-cell Lymphoma

Interventions: Drug: Clofarabine

First Posted Date: 2008-03-26

Last Posted Date: 2023-03-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT00644189

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: carboplatin
Drug: Nab-paclitaxel
Drug: Bevacizumab

First Posted Date: 2008-03-25

Last Posted Date: 2017-04-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT00642759

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Biochemical and Physiological Changes Associated With Differing Durations of Relaxation Response Training

Completed

Conditions: Stress

Interventions: Behavioral: Relaxation Response + Stress Management Curriculum

First Posted Date: 2008-03-14

Last Posted Date: 2011-09-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00636129

Locations: 🇺🇸
Benson-Henry Institute for Mind Body Medicine, Boston, Massachusetts, United States

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Ziprasidone
Drug: Placebo

First Posted Date: 2008-03-12

Last Posted Date: 2014-07-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 458

Registration Number: NCT00633399

Locations: 🇺🇸
Massachusetts General Hospital- Depression Clinical and Research Program, Boston, Massachusetts, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

D-Cycloserine Enhancement of Exposure in Social Phobia

Phase 4

Completed

Conditions: Social Anxiety Disorder

Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT)
Drug: Placebo
Drug: D-Cycloserine

First Posted Date: 2008-03-12

Last Posted Date: 2014-05-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 169

Registration Number: NCT00633984

Locations: 🇺🇸
Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Boston, Massachusetts, United States

The Oral Contraceptive Pill for Premenstrual Worsening of Depression

Not Applicable

Completed

Conditions: Premenstrual Syndrome
Depression

Interventions: Drug: Drospirenone and ethinyl estradiol
Drug: Placebo

First Posted Date: 2008-03-12

Last Posted Date: 2017-03-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT00633360

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy